Browse the evidence

Hypothalamic inflammation disrupts the blood-brain barrier (BBB), allowing peripheral inflammatory signals and immune cells to enter the brain, further exacerbating metabolic deregulation.

Long-term high-fat diets damage the brain's protective barrier, letting inflammation in. Reducing saturated fats may help maintain this barrier.

Rapid and large initial weight loss is associated with better long-term weight maintenance compared to slow, gradual weight loss.

Do not be afraid of losing weight quickly. Evidence shows that rapid initial loss does not lead to worse long-term results and may actually help you maintain a lower weight. Focus on achieving a significant deficit rather than slowing down to avoid 'rebound'.

Physical education classes in their current format do not reduce or prevent childhood obesity.

Do not rely on standard school PE to prevent obesity. It is generally ineffective. To impact weight, physical activity must be substantial in quantity, intensity, and duration, which current PE formats rarely achieve.

Setting realistic weight-loss goals does not improve weight-loss outcomes compared to ambitious goals.

Do not lower your goals to 'realistic' levels. Setting ambitious goals does not lead to worse outcomes and may lead to better weight loss. Focus on achieving significant weight loss rather than setting easily achievable targets.

Age-related gut dysbiosis triggers chronic low-grade inflammation (inflammaging) and innate immune activation, which drives age-related degenerative pathologies and reduces longevity.

Your gut health is not determined by your birth year but by your biological age and lifestyle. Dysbiosis (an imbalance of gut bacteria) triggers inflammation that accelerates aging. To maintain longevity, focus on dietary patterns that support a diverse microbiome and avoid factors like high-glycemic diets or excessive antibiotic use that promote dysbiosis.

Short-chain fatty acids (SCFAs) like butyrate have dual effects on aging: they can promote healthy aging (e.g., via HDAC inhibition) but also contribute to pathology (e.g., neuroinflammation in Parkinson's models) depending on context.

Short-chain fatty acids (SCFAs) from fiber are generally beneficial for metabolic health and aging. However, in specific neurodegenerative conditions, they may contribute to inflammation. Focus on a balanced diet rather than high-dose supplements if you have underlying neurological risks.

Physical activity and sleep duration are highly polygenic traits with significant heritability driven by central nervous system pathways, rather than just metabolic or muscular factors.

Your natural tendency to be active or sedentary has a genetic component, particularly linked to brain function. This doesn't mean you are stuck; it means you might need to work harder or use different strategies to build activity habits than others. Focus on consistency rather than intensity if starting out.

Twelve-week treatment with the GLP-1 analogue liraglutide (1.8 mg/day) reduces hepatic de novo lipogenesis (DNL) and improves adipose tissue insulin sensitivity, thereby decreasing lipotoxicity in patients with biopsy-proven non-alcoholic steatohepatitis (NASH).

For patients with NASH, a 12-week course of liraglutide (titrated to 1.8 mg daily) has been shown to directly reduce the liver's production of new fat (DNL) and improve how fat tissue responds to insulin. This dual action reduces the toxic fat spill-over (lipotoxicity) that drives liver damage. While weight loss occurs, the study suggests direct metabolic benefits on the liver and fat tissue independent of weight change alone.

Supplementation with the trans10cis12 (t10c12) isomer of conjugated linoleic acid (CLA) causes significant insulin resistance and worsens lipid profiles in obese men with the metabolic syndrome.

If you are obese and have signs of metabolic syndrome (like high blood pressure or high triglycerides), avoid supplements containing the trans10cis12 isomer of conjugated linoleic acid (CLA). While marketed for weight loss, this specific isomer has been shown to worsen insulin resistance and lower 'good' HDL cholesterol, potentially increasing your risk for type 2 diabetes and heart disease. Standard CLA mixtures also failed to improve body composition in this group.

In healthy elderly individuals, age-associated deterioration in glucose tolerance is driven by decreased insulin secretion and action, where the severity of insulin resistance is determined by body fatness rather than chronological age itself.

For older adults, maintaining low visceral fat and high aerobic fitness is more critical for glucose tolerance than chronological age. While beta-cell function declines with age, managing body composition can mitigate insulin resistance. Focus on preserving muscle mass and reducing visceral adiposity rather than accepting metabolic decline as inevitable.

Standard exercise interventions (e.g., 3x30min/week vigorous exercise) produce a negligible direct increase in total daily energy expenditure (approx. 5.3%), which is easily offset by minor appetite adjustments, making exercise alone insufficient to reverse obesity trends without compensatory metabolic or behavioral changes.

Do not rely on exercise alone to lose weight. The calories you burn in a typical workout are small compared to your daily needs and can be unconsciously eaten back. To lose weight, you must combine exercise with dietary changes, as exercise's primary value lies in health benefits and supporting other metabolic adaptations, not direct calorie burning.

Single bouts of exercise increase Resting Metabolic Rate (RMR) for a short period (Excess Post-Exercise Oxygen Consumption, EPOC), but this effect is transient and does not significantly contribute to long-term energy balance.

Don't overestimate the 'afterburn' (EPOC) from a workout. It lasts up to 48 hours but is small. Focus on the total energy you burn during the activity and your overall diet, rather than relying on post-exercise metabolic spikes for weight loss.

Pioglitazone, GLP-1 receptor agonists (GLP-1RAs), and SGLT-2 inhibitors are pharmacological agents with potential utility in managing NASH, though GLP-1RAs show more consistent evidence for histological improvement.

If lifestyle changes are insufficient, discuss GLP-1 receptor agonists (like liraglutide or semaglutide) with your doctor. These drugs not only help control blood sugar but have shown the ability to resolve NASH in biopsy-proven cases. They are generally well-tolerated when titrated slowly.

DPP4 inhibitors (gliptins) treat type 2 diabetes by blocking the enzymatic degradation of incretin hormones (GLP-1 and GIP), thereby prolonging their half-life and enhancing glucose-dependent insulin secretion.

DPP4 inhibitors (gliptins) are oral medications for type 2 diabetes that work by keeping your body's natural insulin-boosting hormones active longer. They are generally well-tolerated, do not typically cause weight gain, and carry a low risk of dangerously low blood sugar compared to other treatments.

During exercise, skeletal muscle synthesizes and releases alanine from glucose-derived pyruvate to transport amino groups to the liver, establishing a glucose-alanine cycle that supports hepatic gluconeogenesis without causing generalized hyperaminoacidemia.

During exercise, your muscles convert glucose byproducts (pyruvate) into alanine to send to your liver for energy production. This is a normal, healthy metabolic process called the glucose-alanine cycle. It does not mean your muscles are breaking down; it means they are efficiently recycling fuel. You do not need to intervene with extra protein to stop this; it is a natural regulatory mechanism.

Global dietary micronutrient supplies have improved over the last 50 years, but sub-Saharan Africa is the only region where micronutrient density has declined due to a shift toward lower-density staples like rice and maize.

To improve your diet, prioritize foods that are dense in vitamins and minerals (vegetables, fruits, lean meats, legumes) rather than just filling up on empty calories like refined grains or sugars. In regions where staple crops are low in nutrients, diversifying the diet or using fortification is critical.

Food-frequency questionnaires (FFQs) systematically overestimate the intake of dairy products and vegetables while underestimating cereal and meat intake compared to 7-day diet diaries, with the magnitude of error varying by sex.

If you are tracking your diet for health optimization, a food diary (recording what you eat in real-time) will give you a more accurate picture of your actual intake than trying to estimate your average habits over a year. Be aware that self-reported long-term habits often skew high for healthy foods (veg/dairy) and low for processed/meat items. For precise nutrient tracking, use a diary; for broad lifestyle categorization, an FFQ-style review is sufficient.

Inducible overexpression of VEGF-A in white adipose tissue (WAT) during early high-fat diet exposure promotes angiogenesis, induces a 'browning' phenotype (increased UCP1/PGC1α), and improves systemic metabolic health by enhancing insulin sensitivity and energy expenditure.

This research suggests that maintaining healthy blood vessel density in fat tissue is crucial for metabolic health. While this is a mouse study using genetic modification, it implies that factors supporting healthy vascularization (like exercise) may help prevent the hypoxia and inflammation associated with obesity.

FGF15/19 acts as an endocrine hormone to repress hepatic gluconeogenesis and stimulate glycogen synthesis, functioning as a post-prandial signal that complements insulin.

This paper describes FGF15/19 as a natural hormone released after eating that helps store energy as glycogen and stops the liver from making new glucose. It works alongside insulin but has its own unique pathway. For practical purposes, this highlights the importance of the post-meal state in metabolic health, though no specific intervention is prescribed.

FGF21 is induced by fasting and acts as a glucagon-like hormone to promote ketogenesis, gluconeogenesis, and fatty acid oxidation during starvation.

FGF21 is a hormone that rises when you fast, helping your body burn fat and make ketones for energy. It is a natural part of the starvation response, ensuring you don't run out of glucose.

Pharmacological administration of FGF21 improves insulin sensitivity, reduces hepatic triglycerides, and causes weight loss in obese rodents and primates.

Injecting FGF21 in obese animals improves insulin sensitivity, lowers liver fat, and reduces weight by increasing energy expenditure, even without eating less. This suggests a potential therapeutic avenue for metabolic disease.

Activation of brown adipose tissue (BAT) via beta-3 adrenergic receptor stimulation reduces plasma cholesterol and protects against atherosclerosis, but only in individuals with a functional hepatic apoE-LDL receptor clearance pathway.

Activating brown fat through cold exposure or specific medications can lower cholesterol and protect heart health, but only if your liver is healthy enough to clear the resulting cholesterol particles. If you have genetic conditions affecting your LDL receptors, this mechanism may not work for you.

In healthy young adults, serum adiponectin and resistin concentrations are not significantly associated with total energy intake or macronutrient composition, after controlling for gender and body fat mass.

For healthy young people, changing your carb-to-fat ratio does not appear to significantly change your blood levels of adiponectin or resistin. Focus on maintaining healthy body fat levels instead, as those are the primary drivers of these hormones.

In Type 2 Diabetes, elevated circulating levels of microRNA-144 (miR-144) directly inhibit the expression of Insulin Receptor Substrate 1 (IRS1), thereby impairing insulin signaling and contributing to insulin resistance.

This research identifies a specific molecular mechanism in Type 2 Diabetes where high levels of miR-144 block insulin signaling by reducing IRS1. For patients, this highlights that insulin resistance is driven by specific genetic regulatory failures, not just lifestyle factors. While this paper does not offer a direct treatment, it identifies miR-144 as a potential biomarker for disease severity and a target for future therapies aimed at restoring insulin sensitivity.